Mineralys Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Mineralys Therapeutics, Inc. filed a Current Report on Form 8-K dated May 22, 2024, reporting the results of its 2024 annual meeting of stockholders. The company’s common stock trades on The Nasdaq Stock Market under the symbol MLYS.
Meeting results and key matters
- Director election: Jon Congleton was elected as a Class I director for a three-year term expiring at the 2027 annual meeting.
- Votes for: 26,418,385; votes withheld: 3,775,533; broker non-votes: 1,838,014.
- Independent auditor ratification: Stockholders ratified the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Votes for: 32,025,366; against: 1,187; abstain: 5,379; broker non-votes: 0.
Financial metrics and liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material changes, outlook, and risks
The filing reports the approval of the two submitted stockholder proposals but does not provide new management guidance, an operating outlook, financial contingencies, or material risk updates. The proposals were described in the company’s definitive proxy statement filed April 9, 2024.
Investor verification items
- Verify the final vote totals and the election term for Jon Congleton.
- Confirm Ernst & Young LLP’s appointment as auditor for the fiscal year ending December 31, 2024.
- Review the April 9, 2024 definitive proxy statement for detailed proposal and governance information.
- Consult the company’s periodic reports for financial performance, cash runway, liquidity, and clinical-development updates, which are not included in this Form 8-K.